Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA

Objectives: To determine the factors that may be used as the prognostic parameter for the therapeutic efficacy of neoadjuvant chemotherapy, which can be used to revising the management of early stage cervical cancer patients with large lesions. Methods: This was a retrospective cohort study. The stu...

Full description

Bibliographic Details
Main Authors: Ediwibowo Ambari, Hariyono Winarto, Bambang Sutrisna, Budiningsih Siregar
Format: Article
Language:English
Published: Indonesian Society of Obstetrics and Gynecology 2013-07-01
Series:Indonesian Journal of Obstetrics and Gynecology
Online Access:http://inajog.com/index.php/journal/article/view/357
_version_ 1818440155057356800
author Ediwibowo Ambari
Hariyono Winarto
Bambang Sutrisna
Budiningsih Siregar
author_facet Ediwibowo Ambari
Hariyono Winarto
Bambang Sutrisna
Budiningsih Siregar
author_sort Ediwibowo Ambari
collection DOAJ
description Objectives: To determine the factors that may be used as the prognostic parameter for the therapeutic efficacy of neoadjuvant chemotherapy, which can be used to revising the management of early stage cervical cancer patients with large lesions. Methods: This was a retrospective cohort study. The study was conducted in the Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, University of Indonesia. The subjects were 15 cervical cancer stage IB2 and IIA patients with lesions’ size of > 4 cm, who would be treated with neoadjuvant chemotherapy, consisted of cisplatin 50 mg/m2, vincristine 2 mg/m2 and bleomycin 15 mg regiment. The patients’ response would be evaluated after completing 3 series of chemotherapy. Data was retrieved from medical records and cervical biopsy paraffin blocks and examined histopathologically using IHC staining to see expression of caspase-3 with histoscore assessment score. Data was analyzed by univariate, bivariate analysis. Results: Response to PVB neoadjuvant chemotherapy was found in 5 out of 15 patients. None of the clinicopathology variables can be used to predict response to therapy. Expression of caspase-3 as a marker of apoptosis, can not predict the response of the therapy before administrating neoadjuvant chemotherapy either. There is a significant difference between the levels of caspase-3 in epidermoid carcinoma with adenocarcinoma, with p value of 0.02 (RR 6;95% CI 1.69-21.26). Conclusion: Clinicopathologic factors and the expression of caspase-3 before getting chemotherapy neoadjuvant can not predict the succeed of the therapy. [Indones J Obstet Gynecol 2013; 1-3: 156-60] Keywords: caspase -3, clinicopathologic, early-stage cervical cancer lession in large, neoadjuvant chemotherapy response to therapy
first_indexed 2024-12-14T18:07:51Z
format Article
id doaj.art-cda324ab8ca84242a6ba7704236ad3dc
institution Directory Open Access Journal
issn 2338-6401
2338-7335
language English
last_indexed 2024-12-14T18:07:51Z
publishDate 2013-07-01
publisher Indonesian Society of Obstetrics and Gynecology
record_format Article
series Indonesian Journal of Obstetrics and Gynecology
spelling doaj.art-cda324ab8ca84242a6ba7704236ad3dc2022-12-21T22:52:20ZengIndonesian Society of Obstetrics and GynecologyIndonesian Journal of Obstetrics and Gynecology2338-64012338-73352013-07-0115616010.32771/inajog.v1i3.357357Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIAEdiwibowo Ambari0Hariyono Winarto1Bambang Sutrisna2Budiningsih Siregar3Division of Oncology Gynecology Department of Obstetrics and Gynecology Faculty of Medicine University of DiponegoroFaculty of Medicine Universitas IndonesiaFaculty of Public Health Universitas of IndonesiaFaculty of Medicine University of Indonesia JakartaObjectives: To determine the factors that may be used as the prognostic parameter for the therapeutic efficacy of neoadjuvant chemotherapy, which can be used to revising the management of early stage cervical cancer patients with large lesions. Methods: This was a retrospective cohort study. The study was conducted in the Dr. Cipto Mangunkusumo Hospital, Faculty of Medicine, University of Indonesia. The subjects were 15 cervical cancer stage IB2 and IIA patients with lesions’ size of > 4 cm, who would be treated with neoadjuvant chemotherapy, consisted of cisplatin 50 mg/m2, vincristine 2 mg/m2 and bleomycin 15 mg regiment. The patients’ response would be evaluated after completing 3 series of chemotherapy. Data was retrieved from medical records and cervical biopsy paraffin blocks and examined histopathologically using IHC staining to see expression of caspase-3 with histoscore assessment score. Data was analyzed by univariate, bivariate analysis. Results: Response to PVB neoadjuvant chemotherapy was found in 5 out of 15 patients. None of the clinicopathology variables can be used to predict response to therapy. Expression of caspase-3 as a marker of apoptosis, can not predict the response of the therapy before administrating neoadjuvant chemotherapy either. There is a significant difference between the levels of caspase-3 in epidermoid carcinoma with adenocarcinoma, with p value of 0.02 (RR 6;95% CI 1.69-21.26). Conclusion: Clinicopathologic factors and the expression of caspase-3 before getting chemotherapy neoadjuvant can not predict the succeed of the therapy. [Indones J Obstet Gynecol 2013; 1-3: 156-60] Keywords: caspase -3, clinicopathologic, early-stage cervical cancer lession in large, neoadjuvant chemotherapy response to therapyhttp://inajog.com/index.php/journal/article/view/357
spellingShingle Ediwibowo Ambari
Hariyono Winarto
Bambang Sutrisna
Budiningsih Siregar
Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA
Indonesian Journal of Obstetrics and Gynecology
title Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA
title_full Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA
title_fullStr Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA
title_full_unstemmed Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA
title_short Caspase-3 can not be Used to Predict the Response to Neoadjuvant Chemotherapy Regiment PVB in Cervical Cancer Stage IB-IIA
title_sort caspase 3 can not be used to predict the response to neoadjuvant chemotherapy regiment pvb in cervical cancer stage ib iia
url http://inajog.com/index.php/journal/article/view/357
work_keys_str_mv AT ediwibowoambari caspase3cannotbeusedtopredicttheresponsetoneoadjuvantchemotherapyregimentpvbincervicalcancerstageibiia
AT hariyonowinarto caspase3cannotbeusedtopredicttheresponsetoneoadjuvantchemotherapyregimentpvbincervicalcancerstageibiia
AT bambangsutrisna caspase3cannotbeusedtopredicttheresponsetoneoadjuvantchemotherapyregimentpvbincervicalcancerstageibiia
AT budiningsihsiregar caspase3cannotbeusedtopredicttheresponsetoneoadjuvantchemotherapyregimentpvbincervicalcancerstageibiia